New therapies on the horizon: Targeted protein degradation in neuroscience.

This minireview explores the burgeoning field of targeted protein degradation (TPD) and its promising applications in neuroscience and clinical development. TPD offers innovative strategies for modulating protein levels, presenting a paradigm shift in small-molecule drug discovery and therapeutic interventions. Importantly, small-molecule protein degraders specifically target and remove pathogenic proteins from central nervous system cells without the drug delivery challenges of genomic and antibody-based modalities. Here, we review recent advancements in TPD technologies, highlight proteolysis targeting chimera (PROTAC) protein degrader molecules with proximity-induced degradation event-driven and iterative pharmacology, provide applications in neuroscience research, and discuss the high potential for translation of TPD into clinical settings. Targeted protein degradation is a revolutionary small-molecule approach for neurologic diseases. Gregory et al. highlight cutting-edge advances in PROTAC degrader molecules, showcasing their ability to cross the blood-brain barrier and selectively degrade disease-causing proteins by design. Targeted protein degradation is compared and contrasted to other modalities aimed at treating neurodegenerative disorders. [ABSTRACT FROM AUTHOR]